

What is NMOSD?

Neuromyelitis optica spectrum disorder (NMOSD) is a rare and debilitating autoimmune disease driven by severe, recurrent central nervous system (CNS) attacks which can result in blindness, paralysis, and death.¹



Globally, NMOSD affects approximately **0.5-4** in every **100,000** people^{2,3}



Over **10,000** of these people live in **Europe**⁴



Median age of disease onset is **40**⁵



Women are **9x more likely** to be impacted than men⁶



75% of seropositive patients with NMOSD may **experience pain**⁷



41% of seropositive patients with NMOSD may become **legally blind** in at least one eye **5 years after disease onset**⁸



41% of patients have also reported an **initial misdiagnosis of MS (multiple sclerosis)**⁹



References: 1. Ajmera MR, et al. Evaluation of comorbidities and health care resource use among patients with highly active neuromyelitis optica. *J Neurol Sci.* 2018;384:96–103. 2. Etemadifar M, et al. Epidemiology of neuromyelitis optica in the world: a systematic review and meta-analysis. *Mult Scler Int.* 2015;2015:174720. 3. Mori M, et al. Worldwide prevalence of neuromyelitis optica spectrum disorders. *Journal of Neurology, Neurosurgery & Psychiatry.* 2018;89:555–556. 4. EAfPA (European Alliance for Patient Access). 2022. Unmet needs in Neuromyelitis Optica Spectrum Disorders in Europe [online] Available at: <https://gafpa.org/wp-content/uploads/2022/02/EAfPA-NMOSD-Jan2022.pdf> Last accessed: 20 September 2022. 5. Krumbholz M, et al. Very late-onset neuromyelitis optica spectrum disorder beyond the age of 75. *J Neurol.* 2015;262(5):1379–1384. 6. Wingerchuk DM. Neuromyelitis optica: effect of gender. *J Neurol Sci.* 2009;286(1-2):18–23. 7. Ayzenberg I, et al. Pain, depression, and quality of life in neuromyelitis optica spectrum disorder: a cross-sectional study of 166 AQP4 antibody-seropositive patients. *Neurol Neuroimmunol Neuroinflamm.* 2021;8(3):e985. 8. Jiao Y, et al. Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. *Neurology.* 2013;81:1197–1204. 9. Beekman J, et al. Neuromyelitis optica spectrum disorder: patient experience and quality of life. *Neurol Neuroimmunol Neuroinflamm.* 2019;6(4).

AMGEN